RYR2 and catecholaminergic polymorphic ventricular tachycardia: Also, advanced in vivo validation should be undertaken in arrhythmia-prone models such as RyR2 or CASQ2 mutant mice for catecholaminergic polymorphic ventricular tachycardia (CPVT), hERG- or KCNQ1/KCNE1-mutant long QT models, coronary artery ligation/reperfusion paradigms, pressure overload (TAC)-induced heart failure, streptozotocin-induced or db/db diabetic cardiomyopathy, spontaneously hypertensive rats, and large-animal post-myocardial infarction canine or porcine systems, to establish translational fidelity of EGCG’s electrophysiological effects.